These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3123585)

  • 1. Fibrinolysis abnormalities in systemic lupus erythematosus and their relation to vasculitis.
    Awada H; Barlowatz-Meimon G; Dougados M; Maisonneuve P; Sultan Y; Amor B
    J Lab Clin Med; 1988 Feb; 111(2):229-36. PubMed ID: 3123585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial cell activation in cutaneous vasculitis.
    Jurd KM; Stephens CJ; Black MM; Hunt BJ
    Clin Exp Dermatol; 1996 Jan; 21(1):28-32. PubMed ID: 8689765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor-1 is associated with impaired endothelial function in women with systemic lupus erythematosus.
    Somers EC; Marder W; Kaplan MJ; Brook RD; McCune WJ
    Ann N Y Acad Sci; 2005 Jun; 1051():271-80. PubMed ID: 16126968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders.
    Jurado M; Páramo JA; Gutierrez-Pimentel M; Rocha E
    Thromb Haemost; 1992 Nov; 68(5):516-20. PubMed ID: 1455397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
    Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
    J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis.
    Francis RB; McGehee WG; Feinstein DI
    Thromb Haemost; 1988 Jun; 59(3):412-4. PubMed ID: 3142079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus.
    Heshmat NM; El-Kerdany TH
    Pediatr Allergy Immunol; 2007 Jun; 18(4):346-53. PubMed ID: 17346298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predisposing factors to thrombosis in systemic lupus erythematosus: possible relation to endothelial cell damage.
    Angles-Cano E; Sultan Y; Clauvel JP
    J Lab Clin Med; 1979 Aug; 94(2):312-23. PubMed ID: 458249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis.
    Kamper EF; Kopeikina LT; Koutsoukos V; Stavridis J
    J Rheumatol; 1997 Feb; 24(2):262-8. PubMed ID: 9034981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Status of fibrinolysis in systemic lupus erythematosus].
    Ihle E; Ziemer S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):184-90. PubMed ID: 2427400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects.
    Stegnar M; Mavri A
    Thromb Haemost; 1995 Mar; 73(3):453-7. PubMed ID: 7667828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
    Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
    Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
    Mahmoud RA; El-Gendi HI; Ahmed HH
    Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
    Kuryliszyn-Moskal A; Ciolkiewicz M; Klimiuk PA; Sierakowski S
    Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrophie blanche. A disorder associated with defective release of tissue plasminogen activator.
    Pizzo SV; Murray JC; Gonias SL
    Arch Pathol Lab Med; 1986 Jun; 110(6):517-9. PubMed ID: 3085632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
    Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE
    Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
    Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
    Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.